Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

From the Food and Drug Administration

From the Food and Drug Administration From the Food and Administration Drug New for Sodium tubular each the were worldwide in the Labeling Nitroprus- capsules, containing implanted period side Risk of Tox- The from 1976 1986. The notifica¬ Emphasizes Cyanide progestin capsules through levonorgestrel. The for are inserted beneath the skin of the tion isto thatcardiovas¬ ensure icity: newly approved labeling up¬ program sodium cular arm. The should be re¬ (SNP) highlights surgeons, nitroprusside per implants cardiologists, primary the risk of lethal tox- moved after 5 if new care and are aware cyanide physicians, potentially years and, desired, patients of the associated with extended ofthe ones inserted at that time. The cumula¬ and what to do use icity potential problem about and also reflects new clinical tive annual rate for the and that continue to re¬ drug pregnancy prod¬ it, they attained since the over 5 is a ceive uct information. knowledge drug's ap¬ years 1.1%, indicating up-to-date The for of as com¬ of the involves the In¬ indications effectiveness Part proval. approved high degree program SNP remain as follows: to with other meth¬ ternational immediately pared contraceptive Implant (IRR), op¬ Registry reduce the of in ods. is the blood at erated Medic-Alert pressure patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

From the Food and Drug Administration

JAMA , Volume 265 (7) – Feb 20, 1991

From the Food and Drug Administration

Abstract

From the Food and Administration Drug New for Sodium tubular each the were worldwide in the Labeling Nitroprus- capsules, containing implanted period side Risk of Tox- The from 1976 1986. The notifica¬ Emphasizes Cyanide progestin capsules through levonorgestrel. The for are inserted beneath the skin of the tion isto thatcardiovas¬ ensure icity: newly approved labeling up¬ program sodium cular arm. The should be re¬ (SNP) highlights surgeons, nitroprusside per implants...
Loading next page...
 
/lp/american-medical-association/from-the-food-and-drug-administration-ZDJc5J4qYp

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1991.03460070029012
Publisher site
See Article on Publisher Site

Abstract

From the Food and Administration Drug New for Sodium tubular each the were worldwide in the Labeling Nitroprus- capsules, containing implanted period side Risk of Tox- The from 1976 1986. The notifica¬ Emphasizes Cyanide progestin capsules through levonorgestrel. The for are inserted beneath the skin of the tion isto thatcardiovas¬ ensure icity: newly approved labeling up¬ program sodium cular arm. The should be re¬ (SNP) highlights surgeons, nitroprusside per implants cardiologists, primary the risk of lethal tox- moved after 5 if new care and are aware cyanide physicians, potentially years and, desired, patients of the associated with extended ofthe ones inserted at that time. The cumula¬ and what to do use icity potential problem about and also reflects new clinical tive annual rate for the and that continue to re¬ drug pregnancy prod¬ it, they attained since the over 5 is a ceive uct information. knowledge drug's ap¬ years 1.1%, indicating up-to-date The for of as com¬ of the involves the In¬ indications effectiveness Part proval. approved high degree program SNP remain as follows: to with other meth¬ ternational immediately pared contraceptive Implant (IRR), op¬ Registry reduce the of in ods. is the blood at erated Medic-Alert pressure patients

Journal

JAMAAmerican Medical Association

Published: Feb 20, 1991

There are no references for this article.